ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)

Anders Rosendal Korshoej; Slávka Lukacova; Jens Christian Hedemann Sørensen; Frederik Lundgaard Hansen; Nikola Mikic; Axel Thielscher; Søren Ole Stigaard Cortnum; Trine Lignell Guldberg; Yasmin Lassen-Ramshad; Christian Rahbek; Kare Eg Severinsen; Gorm von Oettingen

ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)

Anders Rosendal Korshoej, Slávka Lukacova, Jens Christian Hedemann Sørensen, Frederik Lundgaard Hansen, Nikola Mikic, Axel Thielscher, Søren Ole Stigaard Cortnum, Trine Lignell Guldberg, Yasmin Lassen-Ramshad, Christian Rahbek, Kare Eg Severinsen, Gorm von Oettingen

Department of Clinical Medicine - The Department of Neurosurgery

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Conference abstract in journal › Research › peer-review

Original language	Danish
Journal	Neuro-Oncology
ISSN	1522-8517
Publication status	Published - Nov 2018

Cite this

Korshoej, A. R., Lukacova, S., Sørensen, J. C. H., Lundgaard Hansen, F., Mikic, N., Thielscher, A., Cortnum, S. O. S., Guldberg, T. L., Lassen-Ramshad, Y., Rahbek, C., Severinsen, K. E., & Oettingen, G. V. (2018). ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1). Neuro-Oncology.

@article{e7a497c6b6c9430cbdfe49476a7efb70,

title = "ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)",

author = "Korshoej, {Anders Rosendal} and Sl{\'a}vka Lukacova and S{\o}rensen, {Jens Christian Hedemann} and {Lundgaard Hansen}, Frederik and Nikola Mikic and Axel Thielscher and Cortnum, {S{\o}ren Ole Stigaard} and Guldberg, {Trine Lignell} and Yasmin Lassen-Ramshad and Christian Rahbek and Severinsen, {Kare Eg} and Oettingen, {Gorm von}",

year = "2018",

month = nov,

language = "Dansk",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

}

Korshoej, AR , Lukacova, S , Sørensen, JCH, Lundgaard Hansen, F, Mikic, N, Thielscher, A, Cortnum, SOS, Guldberg, TL, Lassen-Ramshad, Y, Rahbek, C, Severinsen, KE & Oettingen, GV 2018, 'ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)', Neuro-Oncology.

ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1). / Korshoej, Anders Rosendal ; Lukacova, Slávka ; Sørensen, Jens Christian Hedemann et al.
In: Neuro-Oncology, 11.2018.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)

AU - Korshoej, Anders Rosendal

AU - Lukacova, Slávka

AU - Sørensen, Jens Christian Hedemann

AU - Lundgaard Hansen, Frederik

AU - Mikic, Nikola

AU - Thielscher, Axel

AU - Cortnum, Søren Ole Stigaard

AU - Guldberg, Trine Lignell

AU - Lassen-Ramshad, Yasmin

AU - Rahbek, Christian

AU - Severinsen, Kare Eg

AU - Oettingen, Gorm von

PY - 2018/11

Y1 - 2018/11

M3 - Konferenceabstrakt i tidsskrift

SN - 1522-8517

JO - Neuro-Oncology

JF - Neuro-Oncology

ER -